Regeneron Pharmaceuticals, Inc.’s stock price soars to $598.76, marking a robust 5.25% increase

Regeneron Pharmaceuticals, Inc. (REGN)

598.76 USD +29.85 (+5.25%) Volume: 1.62M

Regeneron Pharmaceuticals, Inc.’s stock price is currently at 598.76 USD, a positive uptick of +5.25% for this trading session, with a trading volume of 1.62M. However, it’s worth noting the stock’s percentage change YTD stands at -15.94%, highlighting a downward trend for the year.

Latest developments on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. has experienced a turbulent period as its first-quarter results fell short due to lower demand for Eylea, causing the stock to slide. Despite facing challenges and a messy quarter ahead, Regeneron’s stock outperformed competitors on a strong trading day. The company reported strong financial results for Q1 2025, but Eylea sales trailed estimates, leading to a decline in stock price. Despite setbacks, Regeneron unveiled a massive $7 billion growth plan as Dupixent sales surged and Eylea HD gained momentum. The European Commission also approved Regeneron’s new multiple myeloma treatment, providing a glimmer of hope amidst the challenges.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma